Stock Research: Pulmonx

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Pulmonx

NasdaqGS:LUNG US7458481014
88
  • Value
    73
  • Growth
    25
  • Safety
    Safety
    82
  • Combined
    80
  • Sentiment
    70
  • 360° View
    360° View
    88
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 88 (better than 88% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Pulmonx are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Pulmonx. The consolidated Value Rank has an attractive rank of 82, which means that the share price of Pulmonx is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 82% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 73. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 70. But the consolidated Growth Rank has a low rank of 25, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 75 of its competitors have better growth. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
82 53 40 21
Growth
25 39 79 43
Safety
Safety
73 44 47 52
Sentiment
70 29 75 26
360° View
360° View
88 36 85 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
48 44 91 62
Opinions Change
69 50 50 50
Pro Holdings
n/a 41 49 24
Market Pulse
43 38 56 31
Sentiment
70 29 75 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
82 53 40 21
Growth
25 39 79 43
Safety Safety
73 44 47 52
Combined
80 36 67 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
18 18 18 18
Price vs. Earnings (P/E)
83 51 22 11
Price vs. Book (P/B)
89 63 56 48
Dividend Yield
1 1 1 1
Value
82 53 40 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
59 79 62 87
Profit Growth
25 34 26 20
Capital Growth
57 48 91 79
Stock Returns
7 17 89 17
Growth
25 39 79 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
58 49 58 63
Refinancing
97 78 65 59
Liquidity
9 16 20 26
Safety Safety
73 44 47 52

Similar Stocks

Discover high‑ranked alternatives to Pulmonx and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Cigna

NYSE:CI
Country: USA
Industry: Health Care Services
Size: XX-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.